Synonym
DBr-1; DBr1; DBr 1
IUPAC/Chemical Name
4-(4-((4-((6-(4-(4-((2-aminoethyl)amino)-2-(1-(4-chlorophenyl)cyclohexyl)quinazolin-7-yl)piperazin-1-yl)-6-oxohexyl)oxy)piperidin-1-yl)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
InChi Key
BJAVCRNLIDSYTK-UHFFFAOYSA-N
InChi Code
InChI=1S/C55H68ClN9O5/c1-62-37-47(43-17-23-58-35-46(43)53(62)67)45-34-49(68-2)38(32-50(45)69-3)36-63-25-18-42(19-26-63)70-31-9-4-6-10-51(66)65-29-27-64(28-30-65)41-15-16-44-48(33-41)60-54(61-52(44)59-24-22-57)55(20-7-5-8-21-55)39-11-13-40(56)14-12-39/h11-17,23,32-35,37,42H,4-10,18-22,24-31,36,57H2,1-3H3,(H,59,60,61)
SMILES Code
COC1=C(C(C2=C3C=NC=C2)=CN(C)C3=O)C=C(OC)C(CN4CCC(OCCCCCC(N5CCN(C6=CC=C7C(N=C(C8(C9=CC=C(Cl)C=C9)CCCCC8)N=C7NCCN)=C6)CC5)=O)CC4)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
970.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Schröder M, Renatus M, Liang X, Meili F, Zoller T, Ferrand S, Gauter F, Li X, Sigoillot F, Gleim S, Stachyra TM, Thomas JR, Begue D, Khoshouei M, Lefeuvre P, Andraos-Rey R, Chung B, Ma R, Pinch B, Hofmann A, Schirle M, Schmiedeberg N, Imbach P, Gorses D, Calkins K, Bauer-Probst B, Maschlej M, Niederst M, Maher R, Henault M, Alford J, Ahrne E, Tordella L, Hollingworth G, Thomä NH, Vulpetti A, Radimerski T, Holzer P, Carbonneau S, Thoma CR. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nat Commun. 2024 Jan 4;15(1):275. doi: 10.1038/s41467-023-44237-4. Erratum in: Nat Commun. 2024 Aug 19;15(1):7109. doi: 10.1038/s41467-024-51317-6. PMID: 38177131; PMCID: PMC10766610.
